Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.06.17	Press Release: Novartis real world study shows -2- (Dow Jones)
20.06.17	Press Release: Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden (Dow Jones)
19.06.17	Press Release: Novartis: Sandoz receives approval -2- (Dow Jones)
19.06.17	Press Release: Novartis: Sandoz receives approval in Europe for Rixathon(R) (biosimilar rituximab) to treat blood cancers and immunological diseases (Dow Jones)
17.06.17	Press Release: Novartis International AG: New -2- (Dow Jones)
17.06.17	Press Release: Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease (Dow Jones)
15.06.17	Press Release: Novartis: FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus(R) (Dow Jones)
15.06.17	Press Release: Novartis' Cosentyx shows sustained -2- (Dow Jones)
15.06.17	Press Release: Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years (Dow Jones)
08.06.17	Press Release: Novartis presents data -3- (Dow Jones)
08.06.17	Press Release: Novartis presents data -2- (Dow Jones)
08.06.17	Press Release: Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting (Dow Jones)
07.06.17	Press Release: Novartis interim results from -2- (Dow Jones)
07.06.17	Press Release: Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL (Dow Jones)
06.06.17	Press Release: Novartis drug Tasigna receives EU -2- (Dow Jones)
05.06.17	Press Release: Novartis announces clinical -2- (Dow Jones)
05.06.17	Press Release: Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer (Dow Jones)
05.06.17	Press Release: Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer (Dow Jones)
04.06.17	Press Release: Novartis landmark study of -3- (Dow Jones)
04.06.17	Press Release: Novartis landmark study of -2- (Dow Jones)
04.06.17	Press Release: Novartis landmark study of Tafinlar(R) + Mekinist(R) demonstrates durable survival benefit at five years in patients with BRAF mutation-positi... (Dow Jones)
02.06.17	Press Release: Novartis presents updated data -2- (Dow Jones)
02.06.17	Press Release: Novartis presents updated data that reinforce the efficacy and safety of Kisqali(R) (ribociclib) plus letrozole as a first-line option for HR+... (Dow Jones)
31.05.17	Press Release: Novartis: Sandoz proposed -2- (Dow Jones)
31.05.17	Press Release: Novartis: Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency (Dow Jones)
31.05.17	Press Release: At the Meet Novartis Management -2- (Dow Jones)
31.05.17	Press Release: At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to beg... (Dow Jones)
30.05.17	Press Release: Novartis next generation CAR-T -2- (Dow Jones)
30.05.17	Press Release: Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients (Dow Jones)
26.05.17	Press Release: Novartis receives FDA approval for -2- (Dow Jones)
26.05.17	Press Release: Novartis receives FDA approval for expanded use of Zykadia(R) in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC) (Dow Jones)
23.05.17	Press Release: Novartis' new analyses reinforce -2- (Dow Jones)
23.05.17	Press Release: Novartis' new analyses reinforce the potential of Ultibro(R) Breezhaler(R) for COPD patients historically treated with steroids (Dow Jones)
19.05.17	Press Release: Novartis receives positive CHMP -2- (Dow Jones)
19.05.17	Press Release: Novartis receives positive CHMP opinion for first-line use of Zykadia(R) in ALK-positive advanced non-small cell lung cancer (NSCLC) (Dow Jones)
18.05.17	Press Release: Novartis data at ASCO, ICML and -2- (Dow Jones)
18.05.17	Press Release: Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care (Dow Jones)
17.05.17	Press Release: Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities (Dow Jones)
11.05.17	Press Release: Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities (Dow Jones)
04.05.17	Press Release: Novartis exercises exclusive -2- (Dow Jones)
04.05.17	Press Release: Novartis exercises exclusive option agreement with Conatus for the treatment of NASH (Dow Jones)
28.04.17	Press Release: Novartis receives FDA approval for -3- (Dow Jones)
28.04.17	Press Release: Novartis receives FDA approval for -2- (Dow Jones)
28.04.17	Press Release: Novartis receives FDA approval for Rydapt(R) in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocyt... (Dow Jones)
26.04.17	Press Release: Novartis: Alcon announces EU -2- (Dow Jones)
26.04.17	Press Release: Novartis: Alcon announces EU launch of CyPass(R) Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) i... (Dow Jones)
25.04.17	GlobeNewswire/Novartis erzielt Umsatzsteigerungen -4- (Dow Jones)
25.04.17	GlobeNewswire/Novartis erzielt Umsatzsteigerungen -3- (Dow Jones)
25.04.17	GlobeNewswire/Novartis erzielt Umsatzsteigerungen -2- (Dow Jones)
25.04.17	GlobeNewswire/Novartis erzielt Umsatzsteigerungen in allen Divisionen (kWk1), wobei Wachstumstreiber wie Cosentyx und Entresto die Einbussen durch Generik... (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert